A detailed history of Hood River Capital Management LLC transactions in Insmed Inc stock. As of the latest transaction made, Hood River Capital Management LLC holds 1,472,555 shares of INSM stock, worth $109 Million. This represents 1.99% of its overall portfolio holdings.

Number of Shares
1,472,555
Previous 1,315,392 11.95%
Holding current value
$109 Million
Previous $88.1 Million 21.97%
% of portfolio
1.99%
Previous 2.16%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$62.0 - $79.01 $9.74 Million - $12.4 Million
157,163 Added 11.95%
1,472,555 $107 Million
Q2 2024

Aug 14, 2024

BUY
$22.0 - $69.71 $7.76 Million - $24.6 Million
352,891 Added 36.66%
1,315,392 $88.1 Million
Q1 2024

May 15, 2024

BUY
$25.72 - $29.94 $1.46 Million - $1.7 Million
56,682 Added 6.26%
962,501 $26.1 Million
Q4 2023

Feb 14, 2024

BUY
$23.42 - $31.74 $21.2 Million - $28.8 Million
905,819 New
905,819 $28.1 Million
Q2 2022

Aug 15, 2022

SELL
$17.07 - $25.71 $7.67 Million - $11.6 Million
-449,595 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$20.42 - $28.13 $9,372 - $12,911
459 Added 0.1%
449,595 $10.6 Million
Q4 2021

Feb 14, 2022

BUY
$25.89 - $33.45 $906 - $1,170
35 Added 0.01%
449,136 $12.2 Million
Q3 2021

Nov 15, 2021

SELL
$22.46 - $29.47 $389,141 - $510,597
-17,326 Reduced 3.71%
449,101 $12.4 Million
Q2 2021

Aug 13, 2021

SELL
$24.17 - $36.01 $164,356 - $244,868
-6,800 Reduced 1.44%
466,427 $13.3 Million
Q1 2021

May 17, 2021

SELL
$32.28 - $44.3 $1.56 Million - $2.14 Million
-48,329 Reduced 9.27%
473,227 $16.1 Million
Q4 2020

Feb 16, 2021

BUY
$31.45 - $40.54 $16.4 Million - $21.1 Million
521,556 New
521,556 $17.4 Million

Others Institutions Holding INSM

About INSMED Inc


  • Ticker INSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,476,992
  • Market Cap $10B
  • Description
  • Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...
More about INSM
Track This Portfolio

Track Hood River Capital Management LLC Portfolio

Follow Hood River Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hood River Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Hood River Capital Management LLC with notifications on news.